Single‑Dose, Fasting, Replicate Crossover Bioequivalence Study of Modified‑Release Naproxen 500 mg/Esomeprazole 20 mg Tablet versus Reference Naproxen 500 mg/Esomeprazole 20 mg Film‑Coated Tablet in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of Naproxen 500 mg/Esomeprazole 20 mg modified-release tablets (Antibiotice S.A.) compared to Vimovo® 500 mg/20 mg film-coated tablets (Grunenthal Gmbh) in a fasting state among healthy subjects. Establishing bioequivalence is clinically relevant as it ensures that the generic formulation has the same therapeutic effect and safety profile as the branded product, which is crucial for patient safety and treatment efficacy.

The clinical trial involves **healthy subjects** of both genders, with an age range of 18 to 65 years. The sponsor did not provide information regarding the total number of participants. The trial population was selected to include individuals who are not part of a vulnerable population. Participants are expected to maintain their usual lifestyle, including diet and physical activity, throughout the study. The study does not specify any particular lifestyle considerations or habits that participants must adhere to. Key inclusion or exclusion criteria were not provided by the sponsor.

The clinical trial is designed as a **randomized**, **double-blind**, **controlled** study to evaluate the bioequivalence of Naproxen 500 mg/Esomeprazole 20 mg modified-release tablets compared to Vimovo® 500 mg/20 mg film-coated tablets. The study will involve **healthy subjects** and is categorized as a Phase 2 trial. The trial is expected to commence recruitment on September 1, 2024, and is estimated to conclude by February 1, 2025. Participants will be involved in a crossover replicate design, which allows each subject to receive both the test and reference formulations in a fasting state, ensuring a comprehensive comparison of the pharmacokinetic profiles.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on predefined criteria. Following successful screening, subjects will be randomized to receive either the test or reference product in the first period, followed by a washout phase, and then crossover to the alternate product in the subsequent period. Each treatment period will include a series of follow-up visits to monitor safety and collect pharmacokinetic data. The end-of-study visit will occur after the final treatment period, where comprehensive assessments will be conducted to ensure participant safety and gather final data.

The expected length of participant involvement is approximately five months, encompassing the screening, treatment, and follow-up phases. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to maintain rigorous scientific standards while ensuring the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on September 1, 2024, with an estimated completion date of February 1, 2025. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the therapeutic impact of the intervention over the course of the study period. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.